Assignee
INTRADIGM CORP
US·6 granted patents·21 pending applications·60 citations·filing 2003–2011
Top patents by PatentIndex Score
27 records- 0192US7534878B2Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2007·Granted May 19, 2009·22 cites·32 claims
- 0289US7893244B2Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2008·Granted Feb 22, 2011·7 cites·29 claims
- 0389US7723316B2Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2007·Granted May 25, 2010·12 cites·47 claims
- 0488US7786092B2Composition and method of RNAi therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2009·Granted Aug 31, 2010·11 cites·27 claims
- 0584US7893243B2Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2007·Granted Feb 22, 2011·6 cites·35 claims
- 0670US7781414B2Targets for tumor growth inhibitionINTRADIGM CORP·Filed 2004·Granted Aug 24, 2010·2 cites·31 claims
- 0759US2010203036A1Targets for tumor growth inhibitionINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 0852US2011053861A1Compositions comprising nuclear factor-kappa b (nf-kb) sirna and methods of useINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 0952US2011053862A1Compositions comprising survivin sirna and methods of use thereofINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 1052US2011124710A1Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseasesINTRADIGM CORP·Filed 2011·Application pending·0 cites
- 1152US2011065644A1Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of useINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 1251US2010210710A1THERAPEUTIC siRNA MOLECULES FOR REDUCING VEGFR1 EXPRESSION IN VITRO AND IN VIVOINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 1351US2011190375A1Compositions comprising cmyc sirna and methods of use thereofINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 1450US2011046067A1COMPOSITIONS COMPRISING HUMAN EGFR-siRNA AND METHODS OF USEINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 1550US2010280097A1Compositions comprising hif-1 alpha sirna and methods of use thereofINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 1650US2011105588A1Compositions comprising notch1 sirna and methods of use thereofINTRADIGM CORP·Filed 2009·Application pending·0 cites
- 1749US2010286241A1Compositions comprising k-ras sirna and methods of useINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 1849US2010298409A1Compositions comprising stat3 sirna and methods of use thereofINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 1949US2010273858A1Compositions comprising stat5 sirna and methods of use thereofINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 2048US2011015249A1Methods and compositions for treatment of cancer and other angiogenesis-related diseasesINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 2147US2010279919A1Compositions comprising human integrin-linked kinase-sirna and methods of use thereofINTRADIGM CORP·Filed 2008·Application pending·0 cites
- 2247US2007219118A1Therapeutic methods for nucleic acid delivery vehiclesINTRADIGM CORP·Filed 2006·Application pending·0 cites
- 2346US2011038849A1Inhibitory polynucleotide compositions and methods for treating cancerINTRADIGM CORP·Filed 2006·Application pending·0 cites
- 2442US2007203082A1RNAI Agents For Anti-SARS Coronavirus TherapyINTRADIGM CORP·Filed 2004·Application pending·0 cites
- 2542US2010028848A1Compositions and Methods of Using siRNA to Knockdown Gene Expression and to Improve Solid Organ and Cell TransplantationINTRADIGM CORP·Filed 2006·Application pending·0 cites
- 2641US2006211637A1Methods of down regulating target gene expression in vivo by introduction of interfering rnaINTRADIGM CORP·Filed 2003·Application pending·0 cites
- 2738US2009247604A1RNAi Therapeutics for Treatment of Eye Neovascularization DiseasesINTRADIGM CORP·Filed 2005·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →